


Hepatitis C: State of Medicaid Access Report Card

Oklahoma

Estimated Number of Individuals Living with Hepatitis C: 94,200¹



Grade	Summary
<p style="font-size: 2em; font-weight: bold; text-align: center;">C</p>	<p>Liver Damage (Fibrosis) Restrictions: Oklahoma imposes no liver damage requirements (F0 or greater) for preferred treatments (Epclusa, and Mavyret). Non-preferred regimens (Daklinza, Harvoni, Olysio, Sovaldi, Technivie, and Viekira PAK/XR) require moderate liver damage (F2 or greater). Additionally, many clinical issues including, but not limited to anemia, surgery, depression, obesity, epilepsy, psychosis, weight management, or severe concurrent medical diseases must be addressed before starting therapy.</p> <p>Sobriety Restrictions: Oklahoma requires screening and counseling for alcohol and substance use as well as the beneficiary to commit to abstain from alcohol and substance use during and after treatment. Patients must agree to random drug testing during treatment.</p> <p>Prescriber Restrictions: Oklahoma requires a prescription be written by or in consultation with a gastroenterologist, infectious disease, or transplant specialist.</p> <p>Recommendations to Improve Patient Access:</p> <ul style="list-style-type: none"> • Completely remove liver damage, sobriety and prescriber requirements. • Maintain transparency regarding hepatitis C coverage requirements. <p><i>Grade Rationale: Oklahoma has improved access to hepatitis C treatment by removing liver damage requirements for preferred Direct Acting Antiviral (DAA) regimens. The state also reduced sobriety restrictions and now requires screening and counseling and a commitment to abstinence. However, Oklahoma still requires many clinical issues to be addressed before a patient begins therapy. A prescription must still be written by or in consultation with a specialist. With these restrictions, patients have some access to treatment.</i></p>

Background

As of June 2017, Oklahoma had 804,514 individuals enrolled in Medicaid and Children’s Health Insurance Program.² Oklahoma Medicaid, known as SoonerCare, operates a Primary Care Case Management (PCCM) system known as SoonerCare Choice and a Fee-For-Service (FFS) program known as SoonerCare Traditional.³ The state does not contract with any Managed Care Organizations. Most beneficiaries, over 74 percent, are enrolled in the PCCM system.⁴ The remaining 26 percent participate in the FFS program.⁵ The state establishes hepatitis C coverage criteria for all Medicaid beneficiaries.

State of Medicaid Hepatitis C Treatment Access

SoonerCare requires prior authorization (PA) and beneficiaries to be at least 18 years old to access treatment (or at least 12 years old to access Harvoni or Sovaldi).⁶ SoonerCare has separate PA forms for each regimen.⁷ Oklahoma allows individuals with no liver damage (F0 or greater) to qualify for treatment with designated preferred regimens (Epclusa and Mavyret).⁸ Vosevi proposed authorization criteria also allows access for individuals diagnosed with F0 or greater.⁹ However, non-preferred treatments still require moderate liver damage (F2 or greater) to access treatment (Daklinza, Harvoni, Olysio, Sovaldi, Technivie, and Viekira PAK/XR).¹⁰ The state requires a prescription to be written by or in consultation with gastroenterologist or infectious disease or transplant specialist.¹¹ Therapy is initially approved for 12 weeks but, for some regimens, will not be granted prior to the tenth day of the month to prevent prescription limit issues from affecting the member’s compliance.¹²

SoonerCare also requires patients, after discussing treatment adherence with the prescriber, to sign the *Hepatitis C Therapy Intent to Treat Contract*, which states that SoonerCare will stop paying for treatment if the patient misses taking his medications for more than three days in a month.¹³ The contract commits a beneficiary not to engage in alcohol or substance use during and after therapy and to acknowledge that random drug testing is required.¹⁴ Additionally, the contract requires female patients and partners to commit to undergo monthly pregnancy tests throughout the patient’s treatment.¹⁵ A beneficiary must “work with one pharmacy” and provide the name of the pharmacy.¹⁶ SoonerCare also requires the designated pharmacy to sign and submit the *Hepatitis C Pharmacy Therapy Agreement* in which the pharmacy commits to counsel a beneficiary on the potential side effects and support the proper administration of the pharmacy benefit.¹⁷ SoonerCare requires patients to be adherent to receive approval for continued treatment.¹⁸ Prescribers must submit a Hepatitis C Therapy Continuation Prior Authorization Form, which must be completed by both the pharmacy and prescriber, to be considered for approval of extended treatment.¹⁹

Liver Damage (Fibrosis) Restrictions

SoonerCare eliminated liver damage requirements (F0 or greater) for preferred treatments (Epclusa and Mavyret).²⁰ Vosevi proposed authorization criteria also allows access for individuals diagnosed with F0 or greater.²¹ However, non-preferred treatments (Daklinza, Harvoni, Olysio, Sovaldi, Technivie, and Viekira PAK/XR) still require moderate liver damage (F2 or greater) to access treatment.²² Significant other clinical issues including, but not limited to anemia, surgery, depression, obesity, epilepsy, psychosis, weight management, and severe concurrent medical diseases must be addressed before starting therapy.²³

Sobriety Restrictions

SoonerCare requires screening and counseling for alcohol and substance use.²⁴ Beneficiaries must sign and submit the *Hepatitis C Therapy Intent to Treat Contract* that imposes random drug testing throughout treatment and commits the individual to be abstinent during and after therapy.²⁵

Provider Restrictions

SoonerCare requires a prescription to be written by a gastroenterologist or infectious disease or transplant specialist, or the patient to be evaluated by one of the previously designated specialists in the past three months prior to submitting the PA request.²⁶

Points of Contact for Questions & Concerns about Oklahoma's State of Medicaid Hepatitis C Access

Medicaid²⁷: Becky Pasternik-Ikard, Medicaid Director, Oklahoma Health Care Authority, State of Oklahoma
4345 North Lincoln Blvd., Oklahoma City, OK 73105; Telephone: (405) 522-7365

¹ HepVu, Oklahoma State Profile: <https://hepvu.org/state/oklahoma/>

² Medicaid and CHIP in Oklahoma, By-State, Medicaid.gov (Accessed June 2017): <https://www.medicaid.gov/medicaid/by-state/stateprofile.html?state=oklahoma>

³ Programs, Oklahoma Health Care Authority (Accessed June 2017): <http://www.okhca.org/individuals.aspx?id=94&menu=42>

⁴ Share of Medicaid Population Covered Under Different Delivery Systems, Medicaid Managed Care Market Tracker, Henry J. Kaiser Family Foundation, July 1, 2016 (Accessed June 2017):

<http://www.kff.org/medicaid/state-indicator/share-of-medicaid-population-covered-under-different-delivery-systems/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D>

⁵ Ibid. Share of Medicaid Population Covered Under Different Delivery Systems, Medicaid Managed Care Market Tracker

⁶ Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority (Accessed January 2018): <http://okhca.org/providers.aspx?id=16000>

⁷ Prior Authorization Forms, Hepatic Disorders, Oklahoma Health Care Authority (Accessed January 2018): <http://okhca.org/providers.aspx?id=16000>

⁸ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

⁹ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

¹⁰ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

¹¹ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

¹² Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

¹³ Hepatitis C Therapy-Intent to Treat Contract, SoonerCare, Oklahoma Health Care Authority, State of Oklahoma (Accessed January 2018):

<http://okhca.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=20434&libID=19416>; See also: PHARM-28, Hepatitis C Therapy Intent to Treat Contract, Forms (Accessed January 2018): <http://okhca.org/providers.aspx?id=120>

¹⁴ Ibid. Hepatitis C Therapy-Intent to Treat Contract, SoonerCare, Oklahoma Health Care Authority

¹⁵ Ibid. Hepatitis C Therapy-Intent to Treat Contract, SoonerCare, Oklahoma Health Care Authority

¹⁶ Ibid. Hepatitis C Therapy-Intent to Treat Contract, SoonerCare, Oklahoma Health Care Authority

¹⁷ Hepatitis C Pharmacy Therapy Agreement, Oklahoma Health Care Authority, State of Oklahoma, Approved: 03/29/2017 (Accessed January 2018):

<http://okhca.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=20435&libID=19417>; See also: PHARM-29, Hepatitis C Therapy Pharmacy Agreement, Forms (Accessed January 2018): <http://okhca.org/providers.aspx?id=120>

¹⁸ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

¹⁹ Hepatitis C Therapy Continuation Prior Authorization Form, SoonerCare, Oklahoma Health Care Authority, State of Oklahoma, Approved: 03/29/2017 (Accessed January 2018):

<http://okhca.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=20436&libID=19418>; See also: PHARM-30, Hepatitis C Therapy Continuation, Forms (Accessed January 2018): <http://okhca.org/providers.aspx?id=120>

²⁰ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²¹ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²² Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²³ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²⁴ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²⁵ Ibid. Hepatitis C Therapy-Intent to Treat Contract, SoonerCare, Oklahoma Health Care Authority

²⁶ Ibid. Hepatitis C Criteria, Hepatic Disorders, SoonerCare, Oklahoma Health Care Authority

²⁷ Oklahoma, Medicaid Directors, National Association of Medicaid Directors (Accessed June 2017): <http://medicaiddirectors.org/about/medicaid-directors/>